Loading...
OTCM
EMMA
Market cap779kUSD
Jul 08, Last price  
0.01USD
1D
-2.81%
1Q
11.00%
IPO
-99.97%
Name

Emmaus Life Sciences Inc

Chart & Performance

D1W1MN
OTCM:EMMA chart
P/E
—
P/S
0.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.54%
Rev. gr., 5y
-11.68%
Revenues
12m
-25.22%
175,500238,400773,500700,100638,500745,900115,000130,900135,100100,10085,100128,5001,316,00022,752,00023,167,00020,610,00018,390,00029,597,00016,653,00012,453,000
Net income
-7m
L+16.10%
-436,000-3,279,100-5,371,000-8,522,000-8,174,000-8,867,000-3,407,000-10,907,000-2,662,800-3,379,400-5,941,000-7,112,800-9,599,000-54,842,0001,354,000-15,946,000-10,625,000-3,733,000-6,453,000-7,492,000
CFO
-11k
L-99.52%
-86,991-2,958,900-3,656,900-4,613,600-4,910,600-4,165,600-2,630,500-3,036,200-3,271,100-2,114,800-2,978,400-4,792,100-9,038,680-4,523,000-2,451,000-1,254,000-5,073,000-1,503,000-2,286,000-11,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
URL
https://www.emmausmedical.com/
IPO date
May 09, 2000
Employees
54
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT